Why the study?
In secondary stroke prevention, clinicians must sometimes extrapolate clinical trial results into everyday practice or face scenarios where trials have not provided sufficient information to guide treatment decisions.
What are the therapeutic considerations for secondary stroke prevention in scenarios lacking clear clinical trial evidence?
What are the therapeutic considerations for secondary stroke prevention in scenarios lacking clear clinical trial evidence?
This review highlights key clinical dilemmas in secondary stroke prevention where evidence from randomized trials may be insufficient or requires careful extrapolation.
Answers are grounded in this paper and cite their sources.
Requires individualized decisions amid evidence gaps in secondary stroke prevention; leaves open resolution of these dilemmas by future trials.
Secondary stroke prevention encompasses many approaches, including antithrombotic therapy, risk factor management, and a healthy lifestyle. Recommendations are typically based on the results of randomized clinical trials that provide evidence of benefit. However, in some situations, clinicians extrapolate the results of clinical trials into everyday practice, or trials have not provided sufficient information to make treatment decisions. This review will discuss 4 scenarios: dual-antiplatelet therapy, the perils of combining antiplatelet and anticoagulation, indications for statin therapy, and therapeutic considerations for patients with paroxysmal atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Vu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: